TROV TrovaGene Inc.

1.07
+0.06  (+6%)
Previous Close 1.01
Open 1.01
Price To Book 1.49
Market Cap 10,925,061
Shares 10,210,337
Volume 83,293
Short Ratio
Av. Daily Volume 640,367
Stock charts supplied by TradingView

NewsSee all news

  1. Trovagene Announces Three New Nominees for Election to Board of Directors

    SAN DIEGO, March 5, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment

  2. Trovagene Announces Fourth Quarter and Full-Year 2019 Results

    SAN DIEGO, Feb. 27, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment

  3. Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients

    SAN DIEGO, Feb. 13, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including prostate, colorectal, and

  4. Trovagene to Present New Clinical Data for Onvansertib in Metastatic Castration-Resistant Prostate Cancer at ASCO Genitourinary Cancers Symposium

    SAN DIEGO, Feb. 5, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including prostate, colorectal, and

  5. Trovagene Receives Approximately $1.45 Million From Exercise of Warrants

    SAN DIEGO, Jan. 29, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 biomarker data to be presented at AACR April 24-29, 2020. Efficacy data due at EHA June 11-14, 2020.
Onvansertib (PCM-075)
Acute Myeloid Leukemia (AML)
Phase 2 biomarker data to be presented at AACR April 24-29, 2020.
Onvansertib (PCM-075) and Zytiga
Prostate cancer
Phase 1b/2 data presented at ASCO-GI noted 1/5 partial responses, 4/5 with stable disease.
Onvansertib, Folfiri and Avastin (bevacizumab)
KRAS-Mutated Colorectal Cancer

Latest News

  1. Trovagene Announces Three New Nominees for Election to Board of Directors

    SAN DIEGO, March 5, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment

  2. Trovagene Announces Fourth Quarter and Full-Year 2019 Results

    SAN DIEGO, Feb. 27, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment

  3. Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients

    SAN DIEGO, Feb. 13, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including prostate, colorectal, and

  4. Trovagene to Present New Clinical Data for Onvansertib in Metastatic Castration-Resistant Prostate Cancer at ASCO Genitourinary Cancers Symposium

    SAN DIEGO, Feb. 5, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including prostate, colorectal, and

  5. Trovagene Receives Approximately $1.45 Million From Exercise of Warrants

    SAN DIEGO, Jan. 29, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment

  6. Onvasertib Demonstrates Effectiveness as Pan-KRAS Inhibitor with Confirmed Tumor Regression and Clinical Benefit Achieved in KRAS-Mutated mCRC Patients

    SAN DIEGO, Jan. 27, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company targeting cancers that are both highly prevalent and in need of new effective treatment options

  7. Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers Symposium

    SAN DIEGO, Jan. 21, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including colorectal, prostate and

  8. Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASH

    SAN DIEGO, Dec. 9, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment

  9. Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in Acute Myeloid Leukemia (AML)

    SAN DIEGO, Dec. 4, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of

  10. Trovagene Presents Positive Data in Metastatic Prostate Cancer Phase 2 Trial Showing Clinical Response in Patients Resistant to Zytiga®

    SAN DIEGO, Nov.14, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment

  11. Trovagene Announces Third Quarter 2019 Results and Highlights

    SAN DIEGO, Nov. 7, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of

  12. Trovagene Announces Data from Acute Myeloid Leukemia (AML) Phase 1b/2 Trial of Onvansertib Chosen for Oral Presentation at ASH 2019 Annual Meeting

    SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment

  13. Trovagene Announces Positive Response to Treatment in Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer

    SAN DIEGO, Oct. 22, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment

  14. Data Presented at ESMO Provides Rationale for Clinical Trial of Onvansertib in Subset of Patients with Highly-Aggressive Triple Negative Breast Cancer (TNBC)

    SAN DIEGO, Oct. 2, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of

  15. Trovagene Presents Overview of Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC) at ESMO

    SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of

  16. Positive Data from Trovagene Phase 1b/2 Study of Onvansertib Featured in Oral Presentation at European Society for Medical Oncology (ESMO) Conference

    SAN DIEGO, Sept. 30, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment

  17. Trovagene Announces Successful Completion of Phase 1b Trial of Onvansertib in Acute Myeloid Leukemia (AML) and Initiation of Patient Enrollment in Phase 2

    SAN DIEGO, Sept. 19, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment

  18. Trovagene to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    SAN DIEGO, Sept. 3, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment

  19. Trovagene Presents Positive Clinical Data from Ongoing Phase 2 Study of Onvansertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    SAN DIEGO, Aug. 26, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment